[Drug delivery systems for cancer chemotherapy].
Various types of drug delivery system (DDS) for antitumor drugs have been developed to reduce severe systemic toxicities and to enhance antitumor effects by improving their pharmacokinetics. In this paper, outlines are first given of the concept and design of DDS, focusing on polymeric antitumor drugs (macromolecular prodrugs) and then describing the superior DDS effects shown in preclinical studies of DE-310, a DDS optimized for the camptothecin analogue DX-8951. Clinical trials of DE-310 are now ongoing in the USA and Europe.
Inoue
Kazuhiro
K
New Product Research Laboratories III, Daiichi Pharmaceutical Co., Ltd, Tokyo, Japan.
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000493:pharmacokinetics; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems; D015195:Drug Design; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D010316:Particle Size
D000972:Antineoplastic Agents, Phytogenic; C452060:DE-310 cpd; C095887:exatecan; D002166:Camptothecin